5 Top Losers In Healthcare Sector (ZFGN, TNXP, ENZ...)

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Zafgen Inc. (ZFGN)

Lost 37.17% to close Tuesday's (Mar.12) trading at $2.89.

News: The Company has suspended its plans to file an investigational new drug application for ZGN-1258, a candidate for rare metabolic disorders including Prader-Willi syndrome.

The decision to suspend the development of ZGN-1258 was based on a recent, unexpected finding in muscle tissue in four- and six-month long-term rodent toxicology studies.

2. Tonix Pharmaceuticals Holding Corp. (TNXP)

Lost 11.87% to close Tuesday's trading at $2.97.

News: No news

Recent event:

On March 11, the Company announced that it has enrolled the first patients in the RECOVERY study, a new phase III study of Tonmya 5.6 mg for the treatment of posttraumatic stress disorder.

The study is designed to enroll approximately 250 participants across approximately 30 clinical sites in the U.S. The top-line results from this study are expected in the first half of next year.

3. Matinas BioPharma Holdings Inc. (MTNB)

Lost 9.30% to close Tuesday's trading at $1.17.

News: No news

Clinical Trials & Near-term Catalysts:

The Company's lead drug candidate is MAT9001, a uniquely engineered, prescription-only omega-3 fatty acid medication comprising docosa-pentaenoic acid (DPA), eicosapentaenoic acid (EPA) and other omega-3 fatty acids. This compound is under development for therapeutic applications with severe hypertriglyceridemia as the lead indication.

A comparative PK/PD phase II-like study of MAT9001 was completed in 2015, and the Company is planning to advance MAT9001 through thoughtful, well-designed clinical pathways.

4. Tactile Systems Technology Inc. (TCMD)

Tactile Systems Technology is a medical technology company focused on developing medical devices for the treatment of chronic diseases at home.

Lost 9.16% to close Tuesday's trading at $66.14.

News: No news

Recent event:

On February 28, the Company reported financial results for the fourth quarter and full year ended December 31, 2018.

Net income in 2018 increased 13% year-over-year to $6.6 million, compared to $5.9 million in 2017. Full-year 2018 revenue increased 32% year-over-year, to $143.8 million, compared to $109.3 million in 2017.

Looking ahead to 2019, the Company expects annual revenue in the range of $173.0 million to $175.5 million, representing growth of 20% to 22% year-over-year.

5. Enzo Biochem Inc. (ENZ)

Lost 8.74% to close Tuesday's trading at $2.82.

News: The Company announced financial results for the second quarter ended January 31, 2019.

Total revenues for the second quarter were $19.3 million, down from $26.1 million in the prior year quarter.

The GAAP and non-GAAP net loss for the second quarter widened to $8.4 million or $0.18 per share from a GAAP net loss of $0.9 million or $0.02 per share and a non-GAAP net loss of $2.0 million or $0.04 per share a year ago.